<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994368</url>
  </required_header>
  <id_info>
    <org_study_id>4D-CHM-001-NH-0001</org_study_id>
    <nct_id>NCT02994368</nct_id>
  </id_info>
  <brief_title>&quot;Natural History&quot; Study of Choroideremia</brief_title>
  <official_title>A Multicenter Prospective Observational &quot;Natural History&quot; Study in Patients With Choroideremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4D Molecular Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4D Molecular Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the rate of progression of all stages of
      choroideremia using a variety of assessments performed in the clinic including visual field
      measures, specialized photography of the eye and participant-reported visual problems
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of progression of disease</measure>
    <time_frame>2 years</time_frame>
    <description>A variety of psychophysical, anatomical and image-based endpoints</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Choroideremia</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with a clinical diagnosis of choroideremia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals with choroideremia (20/200 or better vision) willing to
             participate in an observational study and meeting the eligibility criteria.

        Exclusion Criteria:

          1. Prior therapy with an AAV vector-based treatment

          2. Pre-existing eye conditions that would: (1) preclude future planned treatment in a
             therapeutic intent clinical trial (i.e. intravitreal injection), (2) interfere with
             the interpretation of study endpoints, and/ or put patient at risk for surgical
             complications

          3. Complicating systemic diseases that would preclude future enrollment in a therapeutic
             intent clinical trial

          4. Any other condition that would not allow the potential subject to complete follow-up
             examinations during the course of the study and, in the opinion of the investigator,
             makes the potential subject unsuitable for the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Francis, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>4D Molecular Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Holt</last_name>
    <phone>(510) 505-2680</phone>
    <email>CHM@4dmoleculartherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retina and Vitreous Associates of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moran Eye Center, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Rogers</last_name>
      <phone>801-581-2352</phone>
      <email>katie.rogers@utah.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retinal degeneration</keyword>
  <keyword>eye</keyword>
  <keyword>REP-1 gene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

